Related Experiment Video

Updated: Apr 3, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.8K

Medicinal Chemistry of Fourth-generation Tyrosine Kinase Inhibitors

Mohamed F Zayed1

  • 1Pharmaceutical Sciences Department, Fakeeh College for Medical Sciences, Fakeeh Care Group, Jeddah 21461, Saudi Arabia.

Mini Reviews in Medicinal Chemistry
|April 1, 2026
PubMed

Insights

Fourth-Generation Tyrosine Kinase Inhibitors (FGTKIs) offer new hope for Non-Small Cell Lung Cancer (NSCLC) by overcoming drug resistance. These advanced inhibitors show potent activity against resistant mutations, improving patient outcomes.

Area of Science:

  • Medicinal Chemistry
  • Oncology
  • Pharmacology

Background:

  • Chemotherapy resistance is a major hurdle in Non-Small Cell Lung Cancer (NSCLC) treatment.
  • This necessitates the development of novel therapeutic strategies.
  • Fourth-Generation Tyrosine Kinase Inhibitors (FGTKIs) have emerged to address these challenges.

Purpose of the Study:

  • To review and analyze the medicinal chemistry of FGTKIs.
  • To explore their rational design, mechanism of action, and Structure-Activity Relationships (SARs).
  • To evaluate their therapeutic potential in overcoming resistance mutations in NSCLC.

Main Methods:

  • Systematic literature search across major medical databases.
  • Integration and analysis of relevant scientific publications.

Main Results:

  • FGTKIs are structurally efficient anticancer agents.
  • They act via allosteric inhibition of Tyrosine Kinases (TKs) through reversible interactions.
  • This results in potent inhibition and improved pharmacokinetic/pharmacodynamic properties.

Conclusions:

  • FGTKIs target mutant-EGFR to overcome tertiary resistant mutations (Del19/T790M/C797S).
  • They possess defined molecular designs and pharmacokinetic profiles.
  • FGTKIs have transformed NSCLC treatment, offering superior efficacy and durability over previous inhibitors.
Keywords:
Medicinal chemistryanti-cancer agentcancer cellfourth-generationreceptortyrosine kinase inhibitors

More Related Videos

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

8.4K
Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.7K

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
68
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.9K
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
20.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
649
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K